Please use this identifier to cite or link to this item:
http://dx.doi.org/10.25673/115100
Title: | Persistent symptoms and risk factors predicting prolonged time to symptom-free after SARS-CoV-2 infection : an analysis of the baseline examination of the German COVIDOM/NAPKON-POP cohort |
Author(s): | Shi, Yanyan Strobl, Ralf Andreas Apfelbacher, Christian Bahmer, Thomas Geisler, Ramsia Heuschmann, Peter Horn, Anna Hoven, Hanno Keil, Thomas Krawczak, Michael Krist, Lilian Lemhöfer, Christina Lieb, Wolfgang Lorenz-Depiereux, Bettina Mikolajczyk, Rafael Montellano, Felipe Andrés Reese, Jens-Peter Schreiber, Stefan Skoetz, Nicole Störk, Stefan Vehreschild, Jörg Janne Witzenrath, Martin Grill, Eva Günther, Ulf Petersmann, Astrid |
Issue Date: | 2023 |
Type: | Article |
Language: | English |
Abstract: | Purpose: We aimed to assess symptoms in patients after SARS-CoV-2 infection and to identify factors predicting prolonged time to symptom-free. Methods: COVIDOM/NAPKON-POP is a population-based prospective cohort of adults whose first on-site visits were scheduled ≥ 6 months after a positive SARS-CoV-2 PCR test. Retrospective data including self-reported symptoms and time to symptom-free were collected during the survey before a site visit. In the survival analyses, being symptom-free served as the event and time to be symptom-free as the time variable. Data were visualized with Kaplan–Meier curves, differences were tested with log-rank tests. A stratified Cox proportional hazard model was used to estimate adjusted hazard ratios (aHRs) of predictors, with aHR < 1 indicating a longer time to symptom-free. Results: Of 1175 symptomatic participants included in the present analysis, 636 (54.1%) reported persistent symptoms after 280 days (SD 68) post infection. 25% of participants were free from symptoms after 18 days [quartiles: 14, 21]. Factors associated with prolonged time to symptom-free were age 49–59 years compared to < 49 years (aHR 0.70, 95% CI 0.56–0.87), female sex (aHR 0.78, 95% CI 0.65–0.93), lower educational level (aHR 0.77, 95% CI 0.64–0.93), living with a partner (aHR 0.81, 95% CI 0.66–0.99), low resilience (aHR 0.65, 95% CI 0.47–0.90), steroid treatment (aHR 0.22, 95% CI 0.05–0.90) and no medication (aHR 0.74, 95% CI 0.62–0.89) during acute infection. Conclusion: In the studied population, COVID-19 symptoms had resolved in one-quarter of participants within 18 days, and in 34.5% within 28 days. Over half of the participants reported COVID-19-related symptoms 9 months after infection. Symptom persistence was predominantly determined by participant’s characteristics that are difficult to modify. |
URI: | https://opendata.uni-halle.de//handle/1981185920/117056 http://dx.doi.org/10.25673/115100 |
Open Access: | Open access publication |
License: | (CC BY 4.0) Creative Commons Attribution 4.0 |
Journal Title: | Infection |
Publisher: | Urban & Vogel |
Publisher Place: | München |
Volume: | 51 |
Issue: | 6 |
Original Publication: | 10.1007/s15010-023-02043-6 |
Page Start: | 1679 |
Page End: | 1694 |
Appears in Collections: | Open Access Publikationen der MLU |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
s15010-023-02043-6.pdf | 1.6 MB | Adobe PDF | View/Open |